Indonesia has one of the fastest-growing pharmaceuticals and healthcare sectors in the ASEAN region, in large part due to the government𝔉’s active role in encouraging deve൩lopment. Still, Indonesia’s healthcare services provision is ...

In Q3 2019 China’s healthcare sector continued to expand, stimulated by further structural reforms. The period saw increased government spending on healthcare, with expenditure on health and family planning growing by 12.1% y/y ꦏto RMB 369.3bn. ...

Malaysia has one of the most developed pharm𝓰aceuticals and healthcare sectors in the ASEAN region. The country operates a dual public-private healthcare system in which the government, under the Ministry of Health (“MoH”), both regulates ...

China’s healthcare sector kept growing over the ꦉsecond quarter of 2019. The period was characterised by increased⛦ government spending on healthcare, with the amount dedicated to health and family planning rising by 5.9% y/y to RMB 534.5bn in Q2 ...

The first quarter of 2019 witnessed ⛎a continuous growth of China’s healthcare sector. The country promoted the implementation of the Healthy China Initiative, as well as ongoing structural reforms in the sector. The period was ch🎃aracterized by ...

China&ꦿrsquo;s healthcare sector continued to grow in Q4 2018, largely stimulated by the expansion of online healthcare services. The growth was attributed to increasing demand for quality healthcare, driven by the country’s strong economic ...

China i🐬s the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...

With 1.4bn population each as of 2017, India and China are the most numerous countries out of the six forming the focus of th♑is report. However, the two countries differ widely in terms of per capita GDP, with that of China being more than twice that ...

India’s is the world’s 10th-largest pharmaceutical market in US dollar terms - with sales of over USD 25bn in 2017🧸 - and the largest generic drug manufactur▨er and exporter globally. Strong domestic demand and robust exports have ...

In the third quarter of 2018, China’s pharmaceutical and medi꧙cine production declined by 28.5% y/y to 573,000 tonnes, In 2018, many 🃏pharmaceutical producers were affected by the ongoing reform for new chemical drugs classification system, and ...